It’s time for an extended update on the neoantigen space now that we have new clinical data to look at and discuss. There are a variety of approaches being evaluated in the clinic now, from adenoviral vectors to cell therapies to vaccines.
Indeed, we haven’t covered Moderna Therapeutics before as they were rather quiet in preclinical mode, but now they have some initial clinical data in cancer patients, we thought it would be nice to explore the company’s progress, as well as look at where they’re headed with their mRNA platform.
In the hotseat today, we take a look at the latest developments in the neoantigen vaccine field in terms of oncology settings and have an engaging company interview in the spotlight as well.
To learn more and get a heads up on our latest oncology insights and thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
What a wet wet wet start to the annual meeting of the American Society of Hematology (ASH) meeting being held in San Diego – quite a change from the snow in Atlanta at last year’s event!
Either way, does it precipitate a windfall of excellent data?
A lull between the rain – a soggy day in San Diego
Here are some of our early highlights, which include updates on neoantigen vaccines, novel approaches with CAR T cell therapies, NK cell therapies, targeted therapies and more…
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.